Cargando…

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome

SIMPLE SUMMARY: MET is a proto-oncogene and plays an important role on tumor cell survival, proliferation, metastasis, and drug resistance. Patient with MET amplification has shown an inferior outcome comparing to patients without MET amplification. Fluorescence in situ hybridization (FISH) is often...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Wei, Guo, Ming, Tang, Zhenya, Toruner, Gokce A., Cheng, Joanne, Medeiros, L. Jeffrey, Tang, Guilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139916/ https://www.ncbi.nlm.nih.gov/pubmed/35626038 http://dx.doi.org/10.3390/cancers14102433

Ejemplares similares

Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma
por: Esplen, Hillary P., et al.
Publicado: (2023)

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
por: Overbeck, Tobias Raphael, et al.
Publicado: (2020)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients
por: Yin, Xiaolu, et al.
Publicado: (2015)

High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
por: Wu, Shibo, et al.
Publicado: (2020)

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Detection of MET Gene Copy Number in Cancer Samples Using the Droplet Digital PCR Method
por: Zhang, Yanni, et al.
Publicado: (2016)

Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer
por: Sun, Wenze, et al.
Publicado: (2013)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma
por: Huang, Wan-Ting, et al.
Publicado: (2013)

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
por: Oh, Doo-Yi, et al.
Publicado: (2017)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma
por: Santoni-Rugiu, Eric, et al.
Publicado: (2021)

Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer
por: Kang, Byung Woog, et al.
Publicado: (2015)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
por: Zito Marino, Federica, et al.
Publicado: (2020)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
por: Kumaki, Yuichi, et al.
Publicado: (2023)

Is hyperdiploidy a favorable cytogenetics in adults with B‐lymphoblastic leukemia?
por: Chen, Zhining, et al.
Publicado: (2019)

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
por: Lee, H E, et al.
Publicado: (2012)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients
por: Wang, Yanqiu, et al.
Publicado: (2019)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer
por: Fang, Lianghua, et al.
Publicado: (2018)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors
por: Lee, Eui Jin, et al.
Publicado: (2013)

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
por: Sun, Hongna, et al.
Publicado: (2021)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
por: Seo, A N, et al.
Publicado: (2014)

Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma
por: Li, Yingqin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6d7a1svsukedgmkv5f85488f80